We are live on ! Find out more
229.19 USD
-1.68
0.73%
At close Updated Sep 3, 4:00 PM EDT
Pre-market
After hours
229.20
+0.01
0%
1 day
-0.73%
5 days
-3.15%
1 month
6.51%
3 months
22.92%
6 months
-11.26%
Year to date
-6.38%
1 year
-14.87%
5 years
-22.52%
10 years
239.69%
 

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Employees: 11,370

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 35%
Neutral 57.5%
Negative 7.5%
Neutral
PRNewsWire
20 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Neutral
GlobeNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Neutral
PRNewsWire
7 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Neutral
GlobeNewsWire
7 days ago
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed's webcast presentation will begin at approximately 10:00 a.m. (Eastern Time).
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
Neutral
GlobeNewsWire
9 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Neutral
GlobeNewsWire
17 days ago
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Neutral
Seeking Alpha
20 days ago
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week August 16
Neutral
MarketBeat
26 days ago
ResMed Q4 Earnings Call Highlights
ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electronic components and freight.
ResMed Q4 Earnings Call Highlights
Neutral
Zacks Investment Research
27 days ago
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Negative
Reuters
27 days ago
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall ​Street expectations, impacted by suspended ventilator sales and cost pressures.
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Price charts implemented using Lightweight Charts™